Thyrocare Technologies Ltd
Thyrocare Technologies Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly.
From Thyrocare Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business.
- The partnerships business is anticipated to grow about 1.5 times faster than the franchise business, contributing to consolidated mid-teens growth.
- The company aims to maintain growth above market rates by strategic investments in franchisee network expansion and specialty offerings.
- Specialty segments like allergies and genomics are key areas of investment for future growth and market expansion.
- International business (e.g., Tanzania) is growing rapidly, doubling annually, though it remains a small part currently.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans a field expansion with 40 new field personnel expected in the next financial year.
- There are ongoing investments in specialty offerings, including setting up specialty labs and expanding the internal sales and doctor network (currently 80 doctors on staff).
- Capex so far this financial year is approximately INR 20-30 crores, excluding ROU (Right of Use) asset capitalization.
- ROU asset capitalization related to reagent rental machines increased to around INR 22-23 crores this year from INR 13 crores last year.
- Strategy on capex remains unchanged: buy equipment where cost-effective and use reagent rental models where advantageous, e.g., biochemistry on reagent rental, immunoassay machines bought.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected orderbook or pending orders for Thyrocare Technologies Limited.
- However, there is discussion about partnership onboarding and growth:
- The company has onboarded 5 out of 16 insurance TPAs (Third Party Administrators), up from 3 previously.
- The partnership business accounts for around 33% of revenue.
- Business growth expectations remain positive with targeted organic growth of 15-16% over the next 2 years.
2 more points management made on order book & pipeline
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Technologies Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Vijaya Diagnost. (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Child. (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q3 FY26 results?
Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
The company plans a field expansion with 40 new field personnel expected in the next financial year.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.